Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI
Shots:
- The P-I study involves assessing the safety and PK of AT-527 (550 mg- q2- BID) vs PBO for 5 days in 20 healthy volunteers in a ratio (1:1) to treat COVID-19
- The result showed rapid attainment of steady state levels within 2days of dosing- predicted lung AT-9010 levels were consistently above the EC90 level of 0.5 µM for in vitro inhibition
- AT-527 is an orally administered- direct-acting antiviral agent- currently being evaluated in a P-II study for hospitalized patients with moderate COVID-19 and P-II virology study in patients with mild or mod. COVID-19 in an outpatient setting
Ref: Atea Pharma | Image: Atea Pharma
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com